Effect of Denosumab on Bone Health, Vascular Calcification, and Health-Related Quality of Life in Hemodialysis Patients with Osteoporosis: A Prospective Observational Study

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Apr 9

PMID 38592300

Authors

Hyunsook Kim

Eun Ju Lee

Siyun Woo

Sohee Rho

Ji Yong Jung

Affiliations

Soon will be listed here.

Abstract

: Osteoporosis is common in hemodialysis (HD) patients, contributing to cardiovascular risks. Limited research exists on denosumab's efficacy in this group. Our study explores denosumab's effects on bone turnover markers (BTMs) and vascular calcification in chronic kidney disease-mineral bone disorder (CKD-MBD) patients. : In a prospective single-center study, we investigated the effects of denosumab over 2 years on 30 HD patients from a cohort of 185. Annual assessments of bone mineral density (BMD), vascular calcification, and health-related quality of life (HRQL) were conducted and compared with an untreated group. Mineral and bone parameters were analyzed at specific intervals in the treatment group. : Denosumab notably raised femoral BMD in the initial year. Most bone turnover markers (BTMs) decreased, except for osteocalcin. Changes in T50 correlated with BTMs. Pre-denosumab supplementation of calcium and vitamin D helped manage mineral imbalances. Post denosumab, parathyroid hormone (PTH) levels increased initially, stabilizing after 3 months. No significant changes occurred in vascular calcification or HRQL. : Denosumab exhibited varying effects on BMD improvement, with a stronger impact in the first year that diminished in the second year. Early PTH monitoring was crucial, and extending the administrative period may enhance BMD outcomes compared to the general population.

Citing Articles

Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease.

Srisuwarn P, Eastell R, Salam S J Bone Metab. 2024; 31(4):264-278.

PMID: 39701107 PMC: 11658837. DOI: 10.11005/jbm.24.789.

Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting.

Simonini M, Bologna A, Vezzoli G Int Urol Nephrol. 2024; 56(10):3285-3293.

PMID: 38856936 DOI: 10.1007/s11255-024-04110-9.

References

Connelly K, Collister D, Tangri N . Fracture risk and treatment in chronic kidney disease. Curr Opin Nephrol Hypertens. 2018; 27(3):221-225. DOI: 10.1097/MNH.0000000000000411. View

Festuccia F, Jafari M, Moioli A, Fofi C, Barberi S, Amendola S . Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol. 2016; 30(2):271-279. DOI: 10.1007/s40620-016-0334-1. View

Makras P, Polyzos S, Papatheodorou A, Kokkoris P, Chatzifotiadis D, Anastasilakis A . Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2013; 79(4):499-503. DOI: 10.1111/cen.12188. View

PAYNE R, Little A, Williams R, Milner J . Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973; 4(5893):643-6. PMC: 1587636. DOI: 10.1136/bmj.4.5893.643. View

Kim H, Kim A, Ro H, Chang J, Lee H, Chung W . Serum calcification propensity and its association with biochemical parameters and bone mineral density in hemodialysis patients. Kidney Res Clin Pract. 2022; 42(2):262-271. PMC: 10085723. DOI: 10.23876/j.krcp.22.059. View

Ahn S, Park S, Park S, Yoo J, Jung H, Nho J . Osteoporosis and Osteoporotic Fracture Fact Sheet in Korea. J Bone Metab. 2020; 27(4):281-290. PMC: 7746478. DOI: 10.11005/jbm.2020.27.4.281. View

Jamal S, Ljunggren O, Stehman-Breen C, Cummings S, McClung M, Goemaere S . Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011; 26(8):1829-35. DOI: 10.1002/jbmr.403. View

Bezerra de Carvalho K, Vasco R, Custodio M, Jorgetti V, Moyses R, Elias R . Chronic kidney disease is associated with low BMD at the hip but not at the spine. Osteoporos Int. 2019; 30(5):1015-1023. DOI: 10.1007/s00198-019-04864-4. View

Wilson L, Rebholz C, Jirru E, Liu M, Zhang A, Gayleard J . Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med. 2017; 166(9):649-658. DOI: 10.7326/M16-2752. View

10.

Slouma M, Sahli H, Bahlous A, Laadhar L, Smaoui W, Rekik S . Mineral bone disorder and osteoporosis in hemodialysis patients. Adv Rheumatol. 2020; 60(1):15. DOI: 10.1186/s42358-020-0118-0. View

11.

Park H, Kim S, Yong J, Han S, Yang D, Meguro M . Reliability and validity of the Korean version of Kidney Disease Quality of Life instrument (KDQOL-SF). Tohoku J Exp Med. 2007; 211(4):321-9. DOI: 10.1620/tjem.211.321. View

12.

Agatston A, Janowitz W, HILDNER F, Zusmer N, VIAMONTE Jr M, Detrano R . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15(4):827-32. DOI: 10.1016/0735-1097(90)90282-t. View

13.

Chen C, Chen N, Wu F, Wu M . Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study. Osteoporos Int. 2020; 31(8):1507-1516. DOI: 10.1007/s00198-020-05391-3. View

14.

Jiang X, Gruner M, Tremollieres F, Pluskiewicz W, Sornay-Rendu E, Adamczyk P . Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: A systematic review and meta-analysis. Bone. 2017; 99:20-25. DOI: 10.1016/j.bone.2017.02.008. View

15.

McCormick B, Davis J, Burns K . Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis. 2012; 60(4):626-8. DOI: 10.1053/j.ajkd.2012.06.019. View

16.

Aleksova J, Kurniawan S, Vucak-Dzumhur M, Kerr P, Ebeling P, Milat F . Aortic vascular calcification is inversely associated with the trabecular bone score in patients receiving dialysis. Bone. 2018; 113:118-123. DOI: 10.1016/j.bone.2018.05.014. View

17.

Bover J, Bailone L, Lopez-Baez V, Benito S, Ciceri P, Galassi A . Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017; 30(5):677-687. DOI: 10.1007/s40620-017-0404-z. View

18.

Przedlacki J, Buczynska-Chyl J, Kozminski P, Niemczyk E, Wojtaszek E, Gieglis E . The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: a two-year prospective multicenter cohort study. Osteoporos Int. 2018; 29(5):1105-1115. DOI: 10.1007/s00198-018-4406-z. View

19.

. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2019; 7(1):1-59. PMC: 6340919. DOI: 10.1016/j.kisu.2017.04.001. View

20.

Smith E, Ford M, Tomlinson L, Bodenham E, McMahon L, Farese S . Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol. 2013; 25(2):339-48. PMC: 3904573. DOI: 10.1681/ASN.2013060635. View